Symbols

NRXP

NRX Pharmaceuticals·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

High Gross Profit Margin

Significant Net Income Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NRXP

Nrx Pharmaceuticals, Inc.

A clinical stage pharmaceutical company that develops novel therapies to treat central nervous system disorders

Industry

Pharmaceutical

Established Date

05/20/2015

Listing Date

12/04/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.salbergco.com

Security Type

Common stock

Office address

1201 Orange Street, Suite 600, Wilmington, Delaware 19801

Business

Introduction

NRX Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware on May 20, 2015, is a clinical-stage small molecule pharmaceutical company that develops novel therapies for the treatment of central nervous system diseases and life-threatening lung diseases.

Earnings Call

Q2/2025

Estimate EPS-0.23

Actual EPS-0.98

Estimate Revenue--

Actual Revenue--

NRx Pharmaceuticals' Q2 2025: Unpacking Contradictions in Approval Pathways, Expansion Strategies, and Commercial Plans

Aug 20,2025 01:36·
Earnings Decrypt

Q3/2025

Estimate EPS-0.02

Actual EPS-0.27

Estimate Revenue6.08M

Actual Revenue242.00K

NRx Pharmaceuticals' Q3 2025: Contradictions Emerge on Accelerated Approval, Commercialization, and Ketamine Strategies

Nov 17,2025 12:11·
Earnings Decrypt

Company Financials

EPS

NRXP has released its 2025 Q2 earnings. EPS was reported at -0.98, versus the expected -0.23, missing expectations. The chart below visualizes how NRXP has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NRXP has released its 2025 Q3 earnings report, with revenue of 242.00K, reflecting a YoY change of NaN%, and net profit of -5.89M, showing a YoY change of -262.91%. The Sankey diagram below clearly presents NRXP's revenue sources and cost distribution.